All News
Filter News
Found 809,023 articles
-
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
6/1/2020
Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA
-
Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)
6/1/2020
Company believes District Court decision misinterprets federal law and fails to address important legal requirements of the Administrative Procedure Act
-
Karmanos Cancer Institute Resumes All Services as Cases of COVID-19 Decline and Michigan Governor Lifts Restrictions
6/1/2020
As the number of patients who require care for COVID-19 across the state of Michigan decreases and restrictions put in place by the Governor are lifted, Karmanos Cancer Institute continues to offer all cancer care services.
-
Varian Appoints Michael Hutchinson to Senior Vice President, Chief Legal Officer, and Francis R. Facchini, M.D., FSIR to President, Interventional Solutions Business
6/1/2020
Varian announced two executive appointments. Michael Hutchinson has joined the company as Senior Vice President, Chief Legal Officer following the previously communicated retirement plans of John Kuo.
-
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
6/1/2020
Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities
-
Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial
6/1/2020
Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology
-
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
6/1/2020
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced the Portuguese Medicine Regulatory Authority has granted approval for reimbursement of TEGSEDI® for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 01, 2020
6/1/2020
Spero Therapeutics, Inc. announced that on May 29, 2020, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 29,500 shares of its common stock to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.
-
Admedus Changes Name to Anteris Technologies Ltd. Provides Corporate and Clinical Development Update
6/1/2020
Admedus Limited, announced that it has changed the Company’s name to Anteris Technologies Ltd. As of May 22, 2020 Anteris, is trading on the Australian Securities Exchange under the ticker AVR.
-
MedX Launches AGORACOM Online Marketing and Awareness Program
6/1/2020
MedX Health Corp. is pleased to announce that it is implementing an online marketing and awareness program through AGORACOM.
-
ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting
6/1/2020
ChromaDex Corp. announced it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide in Human Health and Disease: The State of the Science on Nutrition Interventions” tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted by the American Society for Nutrition.
-
APhA Swears in Scott J. Knoer as its 13th Chief Executive Officer
6/1/2020
Scott J. Knoer, MS, PharmD, FASHP, was sworn in as the 13th Chief Executive Officer and Executive Vice President of the American Pharmacists Association, during a virtual ceremony witnessed by APhA members and staff.
-
Aurinia Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
6/1/2020
Aurinia Pharmaceuticals Inc. announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 p.m. EDT.
-
The Urology Care Foundation Joins the World in Celebrating Men's Health Month!
6/1/2020
The first of June marks the start of Men's Health Month, a time of year dedicated to the health and wellness of men throughout the world.
-
New Leaders at ASTCT and CIBMTR Provide Guidelines and Measures for Combating COVID-19 and Protecting Transplant Patients
6/1/2020
The American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research outlined their guidelines and measures for combating the spread of COVID-19, while providing protection to transplant patients.
-
Lung Health Foundation Welcomes New Timeline For Patented Medicines Pricing Guidelines
6/1/2020
Protecting treatment access for Canadian lung disease patients a top concern
-
Sage Therapeutics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
6/1/2020
Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 3:00 p.m. ET.
-
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
6/1/2020
Arena Pharmaceuticals, Inc. announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $50.00 per share, including 825,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.
-
Brent Ragans Named President of Ferring US
6/1/2020
Ragans is now responsible for Ferring US commercial, manufacturing and development operations
-
DJO® Launches New DonJoy® X-ROM™ Post-Op Knee Brace
6/1/2020
DJO®, a leading global provider of medical technologies to get and keep people moving, introduces the new DonJoy® X-ROM™ Post-Op Knee Brace.